SCHEMBL364142

SCHEMBL364142

COc1ccc(/C=C/C(=O)c2ccc(C)cc2F)cn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.50
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
MEN1 O00255 2/20 0.48
HPGD P15428 2/20 0.48
KMT2A Q03164 2/20 0.48
CXCL12 P48061 1/20 0.47
ALDH1A1 P00352 1/20 0.47
GAA P10253 1/20 0.47
ALOX12 P18054 1/20 0.47
CTSL P07711 2/20 0.46
NFE2L2 Q16236 1/20 0.46
MAOA P21397 2/20 0.46
MAOB P27338 2/20 0.46
PADI4 Q9UM07 1/20 0.46
TUBB1 Q9H4B7 1/20 0.46
ABCG2 Q9UNQ0 3/20 0.45
MAPT P10636 1/20 0.45
CAPN1 P07384 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL363768 0.88 LMNA (0.63) LMNASMN1; SMN2MEN1HPGDKMT2A
SCHEMBL364871 0.87 MEN1 (0.47) LMNANPC1RAB9ASMN1; SMN2MEN1
SCHEMBL363978 0.87 CXCL12 (0.64) LMNANPC1RAB9ASMN1; SMN2MEN1
SCHEMBL365186 0.84 ABCG2 (0.51) LMNANPC1RAB9ASMN1; SMN2MEN1
SCHEMBL363719 0.80 LMNA (0.52) LMNANPC1RAB9ASMN1; SMN2HPGD
SCHEMBL363188 0.79 MAOB (0.60) MEN1KMT2ACXCL12NFE2L2MAOA
SCHEMBL364403 0.78 SMN1; SMN2 (0.50) LMNANPC1RAB9ASMN1; SMN2MEN1
SCHEMBL1390372 0.76 MAOB (0.54) LMNANPC1RAB9ASMN1; SMN2CTSL
SCHEMBL28608967 0.74 F3 (0.56) LMNANPC1RAB9ASMN1; SMN2MEN1
SCHEMBL363641 0.74 CXCL12 (0.59) LMNANPC1RAB9ASMN1; SMN2CXCL12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2593426-B1 1-HYDROXYIMINO-3-PHENYL-PROPANES HOFFMANN LA ROCHE (CH) 2014-08-20 EP disclosed
US-8765730-B2 1-hydroxyimino-3-phenyl-propanes Hoffmann-La Roche Inc (US) 2014-07-01 US disclosed
EP-2593426-A1 1-HYDROXYIMINO-3-PHENYL-PROPANES F.HOFFMANN-LA ROCHE AG (CH) 2013-05-22 EP disclosed
WO-2012007365-A1 1-HYDROXYIMINO-3-PHENYL-PROPANES F. HOFFMANN-LA ROCHE AG (CH) 2012-01-19 WO disclosed
US-20120010190-A1 1-HYDROXYIMINO-3-PHENYL-PROPANES F. HOFFMANN-LA ROCHE AG (CH) 2012-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010190-A1 1-HYDROXYIMINO-3-PHENYL-PROPANES GPBAR1, GPR119, ADRB1 LMNA 2651/4885NPC1 1074/4885RAB9A 3549/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.